LMTK2 as Potential Biomarker for Stratification between Clinically Insignificant and Clinically Significant Prostate Cancer.
Journal
Journal of oncology
ISSN: 1687-8450
Titre abrégé: J Oncol
Pays: Egypt
ID NLM: 101496537
Informations de publication
Date de publication:
2021
2021
Historique:
received:
04
08
2020
revised:
15
12
2020
accepted:
18
12
2020
entrez:
25
1
2021
pubmed:
26
1
2021
medline:
26
1
2021
Statut:
epublish
Résumé
A set of prostate tumors tend to grow slowly and do not require active treatment. Therefore, stratification between patients with clinically significant and clinically insignificant prostate cancer (PC) remains a vital issue to avoid overtreatment. Fast development of genetic technologies accelerated development of next-generation molecular tools for reliable PC diagnosis. The aim of this study is to evaluate the diagnostic value of molecular biomarkers (CRISP3, LMTK2, and MSMB) for separation of PC cases from benign prostatic changes and more specifically for identification of clinically significant PC from all pool of PC cases in patients with rising PSA levels. Patients (
Identifiants
pubmed: 33488712
doi: 10.1155/2021/8820366
pmc: PMC7803409
doi:
Types de publication
Journal Article
Langues
eng
Pagination
8820366Informations de copyright
Copyright © 2021 Alvydas Vezelis et al.
Déclaration de conflit d'intérêts
The authors confirm that there are no conflicts of interest associated with this publication.
Références
Mol Clin Oncol. 2020 May;12(5):475-484
pubmed: 32257206
Genome Res. 2012 Nov;22(11):2109-19
pubmed: 22975805
J Neurosci. 2003 Jun 15;23(12):4975-83
pubmed: 12832520
Asian J Androl. 2009 Jan;11(1):49-55
pubmed: 19050691
Prostate. 2014 May;74(6):569-78
pubmed: 24464504
Cancer Cell Microenviron. 2015;2(4):
pubmed: 28580371
PLoS One. 2016 Mar 03;11(3):e0150241
pubmed: 26939004
Oncotarget. 2017 Apr 25;8(17):28494-28501
pubmed: 28212531
Mod Pathol. 2013 May;26(5):733-42
pubmed: 23196798
Biochem Biophys Rep. 2017 Sep 21;12:140-150
pubmed: 29090275
J Biol Chem. 2002 Nov 15;277(46):44013-20
pubmed: 12221103
J Hematol Oncol. 2014 Mar 07;7:21
pubmed: 24606912
Cell Oncol (Dordr). 2016 Apr;39(2):97-106
pubmed: 26790878
Oncotarget. 2018 Aug 21;9(65):32534-32550
pubmed: 30197761
Diagnostics (Basel). 2018 Sep 21;8(4):
pubmed: 30698162
Eur J Radiol. 2019 Jun;115:16-21
pubmed: 31084754
Int J Urol. 2018 Sep;25(9):770-779
pubmed: 30129068
Restor Dent Endod. 2015 Nov;40(4):328-31
pubmed: 26587420
World J Oncol. 2019 Apr;10(2):63-89
pubmed: 31068988
J Clin Med. 2019 Oct 11;8(10):
pubmed: 31614612
Rev Urol. 2018;20(1):19-25
pubmed: 29942197
Biosci Rep. 2019 May 21;39(5):
pubmed: 30988068
Front Genet. 2019 Oct 22;10:1018
pubmed: 31695724
Histopathology. 2019 Jan;74(1):135-145
pubmed: 30565298
Nutrients. 2019 Feb 04;11(2):
pubmed: 30720759
Future Sci OA. 2015 Dec 17;2(1):FSO72
pubmed: 28031932
Oncogene. 2010 Jan 14;29(2):188-200
pubmed: 19855435
Oncotarget. 2019 Jan 22;10(7):738-748
pubmed: 30774776
Curr Med Chem. 2019;26(6):1045-1058
pubmed: 30215331
Int Neurourol J. 2014 Jun;18(2):63-7
pubmed: 24987558
Discov Med. 2016 Nov;22(122):281-295
pubmed: 28009970
BMC Cancer. 2010 Jun 22;10:315
pubmed: 20569440
Front Oncol. 2019 Nov 26;9:1263
pubmed: 31850193
J Urol. 2017 Aug;198(2):329-334
pubmed: 28363690
Arch Esp Urol. 2016 Jan-Feb;69(1):19-23
pubmed: 26856734
Onco Targets Ther. 2016 Jul 22;9:4491-503
pubmed: 27524905
Nat Genet. 2008 Mar;40(3):316-21
pubmed: 18264097
Contemp Clin Trials. 2014 Jan;37(1):69-83
pubmed: 24291455
PLoS Genet. 2010 Nov 11;6(11):e1001204
pubmed: 21085629
Nat Rev Urol. 2019 Nov;16(11):645-654
pubmed: 31591549
Oncol Lett. 2016 Jun;11(6):3621-3630
pubmed: 27284364